Scarica l'app Stockscreener
6.815
0.22%
0.005
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BCRX Giù?
Forum
Previsione
Precedente Chiudi:
$6.81
Aprire:
$6.87
Volume 24 ore:
2.65M
Relative Volume:
0.71
Capitalizzazione di mercato:
$1.43B
Reddito:
$557.51M
Utile/perdita netta:
$-35.71M
Rapporto P/E:
-37.86
EPS:
-0.18
Flusso di cassa netto:
$15.50M
1 W Prestazione:
-5.86%
1M Prestazione:
-11.94%
6M Prestazione:
-5.47%
1 anno Prestazione:
-9.84%
Intervallo 1D:
$6.70
$6.92
Intervallo di 1 settimana:
$6.00
$7.32
Portata 52W:
$6.00
$11.31
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Nome
Biocryst Pharmaceuticals Inc
Settore
Telefono
919-859-1302
Indirizzo
4505 EMPEROR BOULEVARD, DURHAM, NC
Confronta BCRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
6.82 | 1.35B | 557.51M | -35.71M | 15.50M | -0.18 |
|
ZTS
Zoetis Inc
|
142.40 | 63.58B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.93 | 43.58B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.3099 | 40.83B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.89 | 23.07B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
432.29 | 19.61B | 3.08B | 1.24B | 1.07B | 25.61 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-01 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-02-25 | Iniziato | Wedbush | Outperform |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-09-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-13 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-02-22 | Aggiornamento | Needham | Hold → Buy |
| 2022-11-02 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2022-08-05 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-08-05 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-04-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2022-04-11 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-12-10 | Iniziato | Oppenheimer | Outperform |
| 2021-08-06 | Downgrade | Jefferies | Buy → Hold |
| 2021-08-03 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-03-01 | Iniziato | Cowen | Outperform |
| 2020-09-29 | Ripresa | JP Morgan | Overweight |
| 2020-06-17 | Iniziato | BTIG Research | Neutral |
| 2020-05-05 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-11-15 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | Ripresa | Piper Jaffray | Overweight |
| 2018-08-08 | Ripresa | JP Morgan | Overweight |
| 2018-07-17 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | Iniziato | Seaport Global Securities | Neutral |
| 2018-01-02 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | Iniziato | Barclays | Equal Weight |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2017-09-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2017-02-16 | Iniziato | Ladenburg Thalmann | Buy |
| 2016-08-12 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Reiterato | FBR Capital | Outperform |
| 2016-02-09 | Downgrade | JP Morgan | Overweight → Neutral |
| 2016-02-09 | Downgrade | Needham | Buy → Hold |
Mostra tutto
Biocryst Pharmaceuticals Inc Borsa (BCRX) Ultime notizie
Is BioCryst Pharmaceuticals Inc. stock bottoming outEarnings Trend Report & Real-Time Buy Signal Alerts - newser.com
Has BioCryst Pharmaceuticals Inc. formed a bullish divergenceWeekly Trend Report & Risk Controlled Daily Trade Plans - newser.com
BioCryst Keen To Take Takeda’s HAE Crown With Astria Acquisition - insights.citeline.com
How BioCryst Pharmaceuticals Inc. stock reacts to oil pricesMarket Volume Report & AI Optimized Trading Strategy Guides - newser.com
BioCryst Pharma (BCRX) Reinstated as 'Buy' by TD Cowen with $30 PT | BCRX Stock News - GuruFocus
Orion, Nuburu, And BioCryst Shares All Tumble On Bad News - Finimize
Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX - TradingView
BioCryst To Buy Astria: A Calculated Gamble That Is Not Without Risk - Seeking Alpha
Teladoc Health Expands Clarity Platform With Workplace Safety Tool - TradingView
BioCryst Pharma price target raised to $26 from $24 at Cantor Fitzgerald - Investing.com Canada
BCRX: JMP Securities Raises Price Target Amid Market Outperforma - GuruFocus
Needham Maintains BioCryst Pharmaceuticals (BCRX) Buy Recommendation - Nasdaq
JMP Securities Maintains BioCryst Pharmaceuticals (BCRX) Market Outperform Recommendation - Nasdaq
What technical models suggest about BioCryst Pharmaceuticals Inc.’s comebackGlobal Markets & Expert Curated Trade Setup Alerts - newser.com
RBC Raises Price Target on BioCryst Pharmaceuticals to $15 From $14, Keeps Outperform Rating - MarketScreener
Astria Therapeutics: Pipeline And Market Potential Post BioCryst Acquisition - Seeking Alpha
BioCryst Pharma (BCRX) Sees Analyst Upgrade with Increased Price Target | BCRX Stock News - GuruFocus
BioCryst to buy Astria Therapeutics for $700m in enterprise value - Pharmaceutical Technology
Will BioCryst Pharmaceuticals Inc. stock maintain growth story2025 Trading Volume Trends & High Accuracy Swing Trade Signals - newser.com
How the Astria Deal Is Shaping the New Story for BioCryst Pharmaceuticals - Yahoo Finance
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Astria Therapeutics, Inc. (NASDAQ: ATXS) - WV News
Oppenheimer downgrades Astria Therapeutics stock rating to Perform on BioCryst acquisition - Investing.com Canada
Biocryst Pharmaceuticals stock hits 52-week low at $6.00 By Investing.com - Investing.com Nigeria
BioCryst’s Unexpected Plunge: Market’s Response - timothysykes.com
Low frequency sounds good to Biocryst in $700M Astria HAE buy - BioWorld MedTech
BioCryst stock price target raised to $15 by RBC on HAE acquisition - Investing.com UK
Form 425 Astria Therapeutics, Filed by: BIOCRYST PHARMACEUTICALS INC - StreetInsider
BioCryst Pharma stock price target raised to $15 by Jefferies on Astria acquisition - Investing.com Canada
BioCryst Stock Tumbles On Astria Buyout, But Analysts Stay Bullish — Retail Cheers The Move As Long-Term Play - Stocktwits
BioCryst to Acquire Astria in $700M Deal - USA Herald
Health Care Stocks Make Small Moves As Industry News Rolls In - Finimize
Covington, Sidley Guide $700M BioCryst Allergic Disease Deal - Law360
BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate' - Benzinga
BioCryst Pharmaceuticals, Inc. agreed to acquire Astria Therapeutics, Inc. for approximately $720 million. - MarketScreener
BioCryst goes ‘all in’ on rare swelling disease with Astria deal - BioPharma Dive
Here’s Why Astria Therapeutics Stock (ATXS) Exploded Today - TipRanks
BioCryst to Acquire Astria Therapeutics in $700 Million Deal - contractpharma.com
BioCryst deepens rare diseases focus with $700 million deal for Astria - Reuters
BioCryst To Acquire Astria Therapeutics - citybiz
Mergers and acquisitions - TradingView
Is the Options Market Predicting a Spike in BioCryst Pharmaceuticals Stock? - Yahoo Finance
BioCryst Pharmaceuticals To Acquire Astria In $700 Million Deal - Finimize
ATXS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Astria Therapeutics, Inc. Is Fair to Shareholders - Business Wire
BioCryst to Acquire Astria Therapeutics for $700 Million Includi - GuruFocus
BioCryst Announces Acquisition of Astria Therapeutics (ATXS) at $13.00 Per Share - GuruFocus
BioCryst (BCRX) to Acquire Astria Therapeutics in $700M Deal - GuruFocus
BioCryst To Acquire Astria Therapeutics In $700M Deal - Stocktwits
BioCryst Pharmaceuticals To Acquire Astria Therapeutics In $700 Million Cash-and-Stock Deal - Nasdaq
BioCryst to acquire Astria Therapeutics for $700 million - Investing.com
BioCryst to acquire Astria Therapeutics for $700 million By Investing.com - Investing.com Canada
BioCryst to Acquire Astria in Deal Valued at $700 Million - MarketScreener
Biocryst Pharmaceuticals Inc Azioni (BCRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.41%
1.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):